Resveratrol and liver disease: Frombench to bedside and community

Liver International

Volumn 30, Issue 8, 2010, Pages 1103-1114

  Bishayee, Anupam ^a   Darvesh, Altaf S ^a   Politis, Themos ^a   McGory, Robb ^a  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

Hepatotoxicity; In vitro; In vivo; Liver disease; Pharmacokinetics; Prevention; Resveratrol; Toxicity; Treatment

Indexed keywords

ALCOHOL; PARACETAMOL; RESVERATROL;

ARTICLE; ATHEROGENIC DIET; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; IRRADIATION; KIDNEY DISEASE; KIDNEY INJURY; LIVER CELL; LIVER DISEASE; LIVER ISCHEMIA; LIVER PARENCHYMA; LIVER TOXICITY; LIVER TRANSPLANTATION; NONHUMAN; REPERFUSION INJURY;

ACETAMINOPHEN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; CARBON TETRACHLORIDE; CYTOKINES; ETHANOL; FREE RADICALS; GLUTATHIONE; HEPATOCYTES; HUMANS; LIVER DISEASES; NF-KAPPA B; STILBENES;

EID: 79551557055     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02295.x     Document Type: Article

References (94)

1. Muriel P, Rivera-Espinoza Y. Beneficial drugs for liver diseases. J Appl Toxicol 2008; 28: 93-103.
2. Miniño AM, Heron MP, Murphy SL, et al. Deaths: Final Data for 2004. National Vital Statistics Report. Hyattsville, MD: National Center for Health Statistics, 2007. p. 55.
3. Heron M, Hoyert DL, Murphy SL, et al. Deaths: Final Data for 2006. National Vital Statistics Report. Hyattsville, MD: National Center for Health Statistics, 2009. p. 57.
4. American Gastroenterological Association. The Burden of Gastrointestinal Diseases. Bethesda, MD: American Gastroenterological Association, 2001.
5. National Institutes of Health. United States Department of Health and Human Services, Cirrhosis. National Digestive Diseases. Bethesda, MD: Information Clearinghouse, 2008.
6. Schuppan D, Afdhal NH. Liver Cirrhosis. Lancet 2008; 371: 838-51.
7. Heidelbaugh JJ, Bruderly M. Cirrhosis and chronic liver failure: Part I diagnosis and evaluation. Am Fam Physician 2006; 74: 756-62.
8. Duvoux C. Liver transplantation: which indications? Which results? Presse Med 2001; 30: 711-6.
9. Rambaldi A, Gludd C. Colchicine for alcoholic and nonalcoholic liver fibrosis and cirrhosis. Cochrane Database Syst Rev 2001; 3: 002148.
10. Rambaldi A, Iaquinto G, Gludd C. Anabolic-androgenic steroids for alcoholic liver disease: a Cochrane Review. Am J Gastroenterol 2002; 97: 1674-81.
11. Lopez PM, Martin P. Update on liver transplantation: indications, organ allocation, and long-term care. Mount Sinai J Med 2006; 73: 1056-66.
12. Weisner RH, Rakela J, Ishitani MB, et al. Recent advances in liver transplantation. Mayo Clin Proc 2003; 78: 197-210.
13. Lorenzini S, Gitto S, Grandini E, et al. Stem cells for end stage liver diseas: how far have we got? World J Gastroenterol 2008; 14: 4593-9.
14. Vitaglione P, Morisco F, Caporaso N, et al. Dietary antioxidant compounds and liver health. Critical Rev Food Sci Nutr 2004; 44: 575-86.
15. Shishodia S, Aggarwal BB, Resveratrol: a polyphenol for all seasons. In: Aggarwal BB, Shishodia S, eds. Resveratrol in Health and Disease. Boca Raton: CRC Press, 2006; 1-16.
16. Harikumar KB, Aggarwal BB. Resveratrol: a multi-targeted agent for age-associated chronic diseases. Cell Cycle 2008; 7: 1020-37.
17. Saiko P, Szakmary A, Jaeger W, et al. Resveratrol and its analog: defense against cancer, coronary disease and neurodegerative maladies or just a fad? Mutat Res 2008; 658: 68-94.
18. Bishayee A. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res 2009; 2: 409-17.
19. Mann CD, Neal CP, Garcea G, et al. Phytochemicals as potential chemopreventive and chemotherapeutic agents in hepatocarcinogenesis. Eur J Cancer Prev 2009; 18: 13-25.
20. Fremont L. Biological effects of resveratrol. Life Sci 2000; 66: 663-7.
21. Dong Z. Molecular mechanisms of the chemopreventive effect of resveratrol. Mutat Res 2003; 523: 145-50.
22. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5: 493-506.
23. Muriel P. NF-kB in liver diseases: a target for drug therapy. J Appl Toxicol 2008; 29: 91-100.
24. Tsai SH, Lin-Shiau SY, Lin JK. Suppression of nitric oxide synthase and the down regulation of the activation of NF kappa B in macrophages by resveratrol. Br J Pharmacol 1999; 126: 673-80.
25. Pendurthi UR, Williams JT, Rao LV. Resveratrol, a polyphenolic compound found in wine, inhibits tissue factor expression in vascular cells: a possible mechanism for the cardiovascular benefits associated with moderate consumption of wine. Arterioscler Thromb Vasc Biol 1999; 19: 419-26.
26. Wadsworth TL, Koop DR. Effects of the wine polyphenolics quercetin and resveratrol on pro-inflammatory cytokine expression in RAW264.7 macrophages. Biochem Pharmacol 1999; 57: 941-9.
27. Bishayee A, Politis T, Darvesh AS. Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma. Cancer Treat Rev 2010; 36: 43-53.
28. Şener G, Toklu HZ, Şehirli AÖ, et al. Protective effects of resveratrol against acetaminophen-induced toxicity in mice. Hepatol Res 2006; 35: 62-8.
29. Kasdallah-Grissa A, Mornagui B, Aouani E, et al. Protective effect of resveratrol on ethanol-induced lipid peroxidation in rats. Alcohol Alcohol 2006; 41: 236-9.
30. 4 treatment in rats. J Appl Toxicol 2008; 28: 35-43.
31. Song EK, Cho H, Kim JS, et al. Diarylhetanoids with free radical scavenging and hepatoprotective activity in vitro from Curcuma longa. Planta Med 2001; 67: 876-7.
32. Yang H, Lee MK, Kim YC. Protective activities of stilbene glycosides from Acer mono leaves against H2O2-induced oxidative damage in primary cultured rat hepatocytes. J Agric Food Chem 2005; 53: 4182-6.
33. Yang H, Sung SH, Kim YC. Two new hepatoprotective stilbene glycosides from Acer mono leaves. J Nat Prod 2005; 68: 101-3.
34. Rubiolo JA, Vega FV. Resveratrol protects primary rat hepatocytes against necrosis induced by reactive oxygen species. Biomed Pharmacother 2008; 62: 606-12.
35. Rubiolo JA, Mithieux G, Vega FV. Resveratrol protects primary rat hepatocytes against oxidative stress damage: activation of the Nrf2 transcription factor and augmented activities of antioxidant enzymes. Eur J Pharmacol 2008; 591: 66-72.
36. Wang GL, Fu YC, Xu WC, et al. Resveratrol inhibits the expression of SREBP1 in cell model of steatosis via Sirt1-FOXO1 signaling pathway. Biochem Biophys Res Commun 2009; 380: 644-9.
37. Kawada N, Seki M, Inoue M, et al. Effect of antioxidants, resveratrol, quercetin, and N-acetylcysteine, on the functions of cultured rat hepatic stellate cells and Kupffer cells. Hepatology 1998; 27: 1265-74.
38. Chen T, Li J, Cao J, et al. A new flavones isolated from Rhizoma smilacis glabrae and the structural requirements of its derivatives for preventing immunological hepatocyte damage. Planta Med 1999; 65: 56-9.
39. Svegliati-Baroni G, Di Sario A, Casini A, et al. The Na1/H1 exchanger modulates the fibrogenic effect of oxidative stress in rat hepatic stellate cells. J Hepatol 1999; 30: 868-75.
40. Godichaud S, Si-Tayeb K, Augé N, et al. The grape-derived polyphenol resveratrol differentially affects epidermal and platelet-derived growth factor signaling in human liver myofibroblasts. Int J Biochem Cell Biol 2006; 38: 629-37.
41. Souza IC, Martins LA, Coelho BP, et al. Resveratrol inhibits cell growth by inducing cell cycle arrest in activated hepatic stellate cells. Mol Cell Biochem 2008; 325: 1-7.
42. Shen Z, Ajmo JM, Rogers CQ, et al. Role of SIRT1 in regulation of LPS- or two ethanol metabolites-induced TNF-a production in cultured macrophage cell lines. Am J Physiol Gastrointest Liver Physiol 2009; 296: S1047-53.
43. Fontana RJ. Acute liver failure including acetaminophen overdose. Med Clin North Am 2008; 92: 761-94.
44. Masubuchi Y, Sugiyama S, Horie T. Th1/Th2 cytokine balance as a determinant of acetaminophen-induced liver injury. Chem-Biol Interact 2009; 179: 273-9.
45. Clemens DL. Effects of ethanol on hepatic cellular replication and cell cycle progression. World J Gastroenterol 2007; 7: 4955-9.
46. Bujanda L, García-Barcina M, Gutiérrez-de Juan V, et al. Effect of resveratrol on alcohol-induced mortality and liver lesions in mice. BMC Gastroenterol 2006; 6: 35.
47. Ajmo J, Liang X, Rogers CQ, et al. Resveratrol alleviates alcoholic fatty liver in mice. Am J Physiol Gastrointest Liver Physiol 2008; 295: G833-42.
48. Raal A, Pokk P, Arend A, et al. Trans-resveratrol alone and hydroxystilbenes of rhubarb (Rheum rhaponticum) root reduce liver damage induced by chronic ethanol administration: a comparative study in mice. Phytother Res 2009; 23: 525-32.
49. Kasdallah-Grissa A, Mornagui B, Aouani E, et al. Resveratrol, a red wine polyphenol, attenuates ethanol-induced oxidative stress in rat liver. Life Sci 2007; 80: 1033-9.
50. Masuda Y. Learning toxicology from carbon tetrachloride-induced hepatotoxicity. Pharm Soc Japan 2006; 126: 885-99.
51. Megli FM, Sabatini K. Mitochondrial phospohlipid bilayer structure is ruined after liver oxidative injury in vivo. FEBS Lett 2004; 573: 68-72.
52. 4 in the rat. J Appl Toxicol 2008; 28: 147-55.
53. Dani C, Oliboni LS, Pasquali MA, et al. Intake of purple juice as a hepatoprotective agent in Wistar rats. J Med Food 2008; 11: 127-32.
54. 4-induced liver lipid peroxidation. J Gastroenterol Hepatol 2009; 24: 618-22.
55. Eybl V, Kotyzova D, Koutensky J. Comparative study of natural antioxidants - curcumin, resveratrol and melatonin - in cadmium-induced oxidative damage in mice. Toxicology 2006; 225: 150-6.
56. Şehirli Ö, Tozan A, Omuttag G, et al. Protective effect of resveratrol against naphthalene-induced oxidative stress in mice. Ecotoxicol Environ Saf 2008; 71: 301-8.
57. Upadhyay G, Singh AK, Kumar A, et al. Resveratrol modulates pyrogallol-induced changes in hepatic toxicity markers, xenobiotic metabolizing enzymes and oxidative stress. Eur J Pharmacol 2008; 596: 146-52.
58. Farghali H, Černý D, Kameniíková L, et al. Rsveratrol attenuates lipopolysaccharide-induced hepatitis in D-galactosamine sensitized rats: role of nitric oxide synthase-2 and heme oxygenase-1. Nitric Oxide 2009; 21: 216-25.
59. Park SH. Nonalcoholic steatohepatitis: pathogenesis and treatment. Korean J Hepatol 2008; 14: 12-27.
60. Ahn J, Kim S, Kwon D, et al. Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet. J Hepatol 2008; 49: 1019-28.
61. Bujanda L, Hijona E, Larzabal M, et al. Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterol 2008; 8: 40.
62. Shang J, Chen L, Xiao F, et al. Resveratrol improves nonalcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacol Sin 2008; 29: 698-706.
63. Cho IJ, Ahn JY, Kim S, et al. Resveratrol attenuates the expression of HMG-CoA reductase mRNA in hamsters. Biochem Biophys Res Commun 2008; 367: 190-4.
64. Deschenes M, Belle SH, Krom RA, et al. Early allograft dysfunction after liver transplantation: a definition andpredictors outcome. National Institute of Diabetes and Digestive and Kidney Diseases. Transplantation 1998; 66: 302-10.
65. Plin C, Tillement J, Berdeaux A, et al. Resveratrol protects against cold ischemia-warm reoxygenation-induced damages to mitochondria and cells in rat liver. Eur J Pharmacol 2005; 528: 162-8.
66. Gedik E, Girgin S, Ozturk H, et al. Resveratrol attenuates oxidative stress and histological alternations induced by liver ischemia/reperfusion in rats. World J Gastroenterol 2008; 14: 7101-6.
67. Hassan-Khabbar S, Cottart C, Wendum D, et al. Postischemic treatment by trans-resveratrol in rat liver ischemia- reperfusion: a possible strategy in liver surgery. Liver Transpl 2008; 14: 451-9.
68. Hassan-Khabbar S, Vamy M, Cottart CH, et al. Protective effect of post-ischemic treatment with trans-resveratrol on cytokine production and neutrophil recruitment by rat liver. Biochimie 2010; 92: 405-10.
69. Wu S, Yu L, Meng K, et al. Resveratrol prolongs allograft survival after liver transplantation in rats. World J Gastroenterol 2005; 11: 4745-9.
70. Wu SL, Yu L, Jiao XY, et al. The suppressive effect of resveratrol on protein kinase C theta in peripheral blood T lymphocytes in a rat liver transplantation model. Transplant Proc 2006; 38: 3052-4.
71. Wu SL, Yu L, Pan C, et al. Apoptosis of lymphocytes in allograft in a rat liver transplantation model induced by resveratrol. Pharmacol Res 2006; 54: 19-23.
72. Kirimlioglu H, Ecevit A, Yilmaz S, et al. Effect of resveratrol and melatonin on oxidative stress enzymes, regeneration and hepatocyte ultrastructure in rats subjected to 70% partial hepatectomy. Transplant Proc 2008; 40: 285-9.
73. Kirimlioglu V, Sozen H, Turkoglu S, et al. Protective effect of resveratrol, a red wine constituent polyphenol, on rats subjected to portal vein thrombosis. Transplant Proc 2008; 40: 290-2.
74. Ara C, Kirimlioglu H, Karabulut AB, et al. Protective effect of resveratrol against oxidative stress in cholestasis. J Surg Res 2005; 127: 112-7.
75. Cenesiz S, Yarim GF, Karabulut AB, et al. Changing of antioxidant enzyme activity on the biliary obstructed rats treated with resveratrol. Dtsch Tier̈arztl Wschr 2007; 114: 345-8.
76. Velioǧlu-Öǧünç A, Şehirli Ö, Toklu H, et al. Resveratrol protects against irradiation-induced hepatic and ileal damage via its anti-oxidative activity. Free Rad Res 2009; 43: 1060-71.
77. Juan ME, Vinardell MP, Planas JM The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J Nutr 2002; 132: 257-60.
78. Crowell JA, Korytko PJ, Morrissey RL, et al. Resveratrolassociated renal toxicity. Toxicol Sci 2004; 82: 614-9.
79. Hebber V, Shen G, Hu R, et al. Toxicogenomics of resveratrol in rat liver. Life Sci 2005; 76: 2299-314.
80. Williams LD, Burdock GA, Edwards JA, et al. Safety studies conducted on high-purity trans-resveratrol in experimental animals. Food Chem Toxicol 2009; 47: 2170-82.
81. Wong YT, Gruber J, Jenner AM, et al. Elevation of oxidative-damage biomarkers during aging in F2 hybrid mice: protection by chronic oral intake of resveratrol. Free Radic Biol Med 2009; 46: 799-809.
82. Horn TL, Cwik MJ, Morrissey RL, et al. Ontogenicity evaluation of resveratrol in p53 (±) (p53 knockout) mice. Food Chem Toxicol 2007; 45: 55-63.
83. Marier JF, Vachon P, Gritsas A, et al. Metabolism and disposition of resveratrol in rats: extend of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther 2002; 302: 369-73.
84. Yu C, Shin YG, Chow A, et al. Human, rat and mose metabolism of resveratrol. Pharm Res 2002; 19: 1907-14.
85. 14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci 2003; 72: 2219-33.
86. Sale S, Verschoyle RD, Boocock D, et al. Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4'-tetramethoxystilbene. Br J Cancer 2004; 90: 736-44.
87. 18F-labelled resveratrol derivative for small animal positron emission tomography. Amino Acids 2005; 29: 415-28.
88. 3H]trans-resveratrol in rat tissues following oral administration. Br J Nutr 2006; 96: 62-70.
89. Wenzel E, Soldo T, Erbersdobler H, et al. Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol Nutr Food Res 2005; 49: 482-94.
90. He H, Chen X, Wang G, et al. High-performance liquid chromatography spectrometric analysis of trans-resveratrol in rat plasma. J Chromatogr 2006; 832: 177-80.
91. Udenigwe CC, Ramprasath VR, Aluko RE, et al. Potential of resveratrol in anticancer and anti-inflammatory therapy. Nutr Rev 2008; 66: 445-54.
92. Rimando AM, Suh N. Biological/chemopreventive activity of stilbenes and their effect on colon cancer. Planta Med 2008; 74: 1635-43.
93. Cottart CH, Nivet-Antoine V, Laguillier-Morizot C, Beaudeux JL. Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res 2010; 54: 7-16.
94. Zhao R, Lie S, Mao S, et al. Study on liver targeting effect of vinegar-baked Radix bupleuri on resveratrol in mice. J Ethnopharmacol 2009; 126: 415-20.